Propecia (Finasteride)

Generic Name

Finasteride

Brand Names

Propecia, Proscar

FDA approval date: December 15, 2006

Classification: 5-alpha Reductase Inhibitor

Form: Tablet

What is Propecia (Finasteride)?

PROPECIA ® is indicated for the treatment of male pattern hair loss in MEN ONLY. Efficacy in bitemporal recession has not been established. PROPECIA is not indicated for use in women. PROPECIA is a 5α-reductase inhibitor indicated for the treatment of male pattern hair loss in MEN ONLY . PROPECIA is not indicated for use in women ( 1, 4.

Approved To Treat

Autosomal Recessive Hypotrichosis

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Phase 2b Randomized, Single-Center, Double Blind, Placebo Controlled, 2-Arm Study to Investigate Orally Administered Combination Therapies (5-alpha Reductase Inhibitor + Raloxifene) Compared With Monotherapy (5-alpha Reductase Inhibitor + Placebo) in Adult Patients With Benign Prostatic Hyperplasia (BPH)

Enrollment Status: Recruiting

Publish Date: March 23, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarker...

A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia.

Enrollment Status: Recruiting

Publish Date: March 04, 2026

Intervention Type: Device

Study Phase: Not Applicable

Summary: Central centrifugal cicatricial alopecia (CCCA) is form of scarring hair loss that predominately affects middle-aged women of African descent.1 . Clinically, the natural progression of CCCA starts at the crown as roughly circular scarred patches, which evolve into scarred areas increasing in size circumferentially. Characteristically, the scar is often smooth and shiny, and the hair density in the...

National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopecia.

Who is this study for: Patients with androgenetic alopecia

Enrollment Status: Recruiting

Publish Date: December 08, 2025

Intervention Type: Drug

Study Drugs: Finlândia Association, Minoxidil, Finasteride

Study Phase: Phase 3

Summary: The purpose of this study is to evaluate the efficacy of Finlândia hair lotion association in the treatment of androgenetic alopecia.

View All Clinical Trials